List of Vibativ drug patents
Vibativ is owned by Cumberland Pharms.
Vibativ contains Telavancin Hydrochloride.
Vibativ has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Vibativ are:
- US6858584
Vibativ was authorised for market use on 11 September, 2009.
Vibativ is available in powder;intravenous dosage forms.
Vibativ can be used as method for treating bacterial infection.
The generics of Vibativ are possible to be released after 01 January, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6635618 | CUMBERLAND PHARMS | Glycopeptide phosphonate derivatives |
Sep, 2023
(7 months from now) | |
| US7531623 | CUMBERLAND PHARMS | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858584 | CUMBERLAND PHARMS | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(5 months ago) | |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 11 September, 2009
Treatment: Method for treating bacterial infection
Dosage: POWDER;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic